NCT02054754

Assessment of Single Doses of Oral Dexanabinol in Healthy Subjects

Assessment of Safety, Tolerability and Pharmacokinetics of Single Doses of Oral Dexanabinol in Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: e-Therapeutics PLC · Industry
• Sex: Male
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to test the safety and observe the pharmacokinetics (distribution and elimination of the drug) of the compound dexanabinol (ETS2101) in healthy male subjects following a single oral dose.

Conditions

• Safety
• Tolerability
• Pharmacokinetics
• Cancer

Interventions

Type	Name	Description
DRUG	Dexanabinol Dose Level 1	Oral formulation of dexanabinol
DRUG	Dexanabinol Dose Level 2	Oral formulation of dexanabinol
DRUG	Dexanabinol Dose Level 3	Oral formulation of dexanabinol
DRUG	Dexanabinol Dose Level 4	Oral formulation of dexanabinol
DRUG	Dexanabinol Dose Level 5	Oral formulation of dexanabinol
DRUG	Placebo

Timeline

• Start date: 2014-01-01
• Primary completion: 2014-09-01
• Completion: 2014-09-01
• First posted: 2014-02-04
• Last updated: 2016-05-23
• Results posted: 2016-05-23

Locations

1 site across 1 country: United Kingdom